Spots Global Cancer Trial Database for Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

Official Title: High Quality Imaging and Dosimetry of Yttrium-90 (90Y) SIRT Using a Digital PET/CT

Study ID: NCT03109262

Conditions

Primary Malignant Liver Neoplasm

Interventions

Computed Tomography (CT)

Positron Emission Tomography (PET)

90-Yttrium (Y-90) Glass Microspheres

Technetium 99mTc albumin aggregated (99mTc-MAA)

Single-photon emission computerized tomography (SPECT) scan

Study Description

Brief Summary: This clinical trial studies how well yttrium-90 (Y90) glass microspheres positron emission tomography (PET)/computed tomography (CT) works in imaging patients with liver tumors . Images produced by PET/CT may provide better information about the distribution of particles, such as Y90 glass microspheres, delivered for selective internal radiation therapy (SIRT) as compared to regular medical care images useing technetium Tc-99m albumin-aggregated single photon emission computed tomography (SPECT)/CT images.

Detailed Description: PRIMARY OBJECTIVES: I. To evaluate the image quality of yttrium-90 (Y90) microspheres PET/CT post SIRT images as compared to technetium Tc-99m albumin aggregated (99mTc MAA) SPECT/CT. SECONDARY OBJECTIVES: I. To determine the superior accuracy in both distribution and dosimetry of Y90 PET/CT post-SIRT imaging compared to 99mTc MAA planar and SPECT/CT imaging. OUTLINE: Immediately after standard of care SIRT, patients receive Y90 glass microspheres and undergo PET/CT over 30 minutes. This study compares the experimental images to the regular medical care images in the same participant.